Coeptis Therapeutics (NASDAQ:ZSQR) Trading Up 7.2% – Still a Buy?

Coeptis Therapeutics Holdings, Inc. (NASDAQ:ZSQR) was up 7.2% during trading on Tuesday . The company traded as high as $10.85 and last traded at $10.81. Approximately 73,918 shares traded hands during mid-day trading, a decline of 27% from the average daily volume of 101,058 shares. The stock had previously closed at $10.08.

Coeptis Therapeutics Price Performance

The firm has a market capitalization of $560.59 million, a PE ratio of -4.33 and a beta of -0.22. The business has a 50-day moving average of $11.90 and a 200 day moving average of $13.02. The company has a current ratio of 3.25, a quick ratio of 3.25 and a debt-to-equity ratio of 0.01.

Coeptis Therapeutics (NASDAQ:ZSQR) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.65) EPS for the quarter. Coeptis Therapeutics had a negative net margin of 810.04% and a negative return on equity of 92.29%. The company had revenue of $0.11 million during the quarter.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ZSQR. Yorkville Advisors Global LP purchased a new position in Coeptis Therapeutics during the third quarter worth about $140,000. Geode Capital Management LLC boosted its holdings in Coeptis Therapeutics by 12.6% during the fourth quarter. Geode Capital Management LLC now owns 42,097 shares of the company’s stock worth $600,000 after purchasing an additional 4,721 shares during the last quarter. Steward Partners Investment Advisory LLC lifted its holdings in Coeptis Therapeutics by 100.0% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 5,000 shares of the company’s stock worth $71,000 after acquiring an additional 2,500 shares during the period. State Street Corp lifted its holdings in Coeptis Therapeutics by 35.0% during the fourth quarter. State Street Corp now owns 26,830 shares of the company’s stock worth $382,000 after acquiring an additional 6,962 shares during the period. Finally, Marshall Wace LLP bought a new stake in Coeptis Therapeutics during the fourth quarter worth $259,000. 13.88% of the stock is currently owned by hedge funds and other institutional investors.

Coeptis Therapeutics Company Profile

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.